Stemline Therapeutics Inc (STML) CEO Ivan Bergstein Sells 55,073 Shares

Stemline Therapeutics Inc (NASDAQ:STML) CEO Ivan Bergstein sold 55,073 shares of the stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $11.11, for a total transaction of $611,861.03. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Ivan Bergstein also recently made the following trade(s):

  • On Thursday, March 7th, Ivan Bergstein sold 6,800 shares of Stemline Therapeutics stock. The stock was sold at an average price of $11.41, for a total transaction of $77,588.00.
  • On Monday, February 25th, Ivan Bergstein sold 22,905 shares of Stemline Therapeutics stock. The stock was sold at an average price of $12.03, for a total transaction of $275,547.15.
  • On Thursday, February 14th, Ivan Bergstein sold 34,132 shares of Stemline Therapeutics stock. The stock was sold at an average price of $10.98, for a total transaction of $374,769.36.

Stemline Therapeutics stock traded up $0.15 during midday trading on Friday, reaching $13.62. The company had a trading volume of 562,180 shares, compared to its average volume of 760,106. The firm has a market capitalization of $429.62 million, a PE ratio of -4.63 and a beta of 1.12. Stemline Therapeutics Inc has a 12-month low of $7.82 and a 12-month high of $20.55.

A number of research analysts recently weighed in on STML shares. BidaskClub lowered shares of Stemline Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, November 16th. HC Wainwright set a $38.00 price target on shares of Stemline Therapeutics and gave the company a “buy” rating in a research note on Wednesday, November 21st. ValuEngine raised shares of Stemline Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, November 23rd. Piper Jaffray Companies started coverage on shares of Stemline Therapeutics in a research note on Monday, November 26th. They issued an “overweight” rating and a $20.00 price target on the stock. Finally, Roth Capital set a $33.00 price target on shares of Stemline Therapeutics and gave the company a “buy” rating in a research note on Sunday, December 2nd. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $25.40.

A number of institutional investors have recently modified their holdings of the stock. Legal & General Group Plc lifted its stake in Stemline Therapeutics by 27.1% in the 4th quarter. Legal & General Group Plc now owns 5,249 shares of the biopharmaceutical company’s stock valued at $50,000 after buying an additional 1,120 shares in the last quarter. Virtus ETF Advisers LLC lifted its stake in Stemline Therapeutics by 11.2% in the 4th quarter. Virtus ETF Advisers LLC now owns 29,723 shares of the biopharmaceutical company’s stock valued at $282,000 after buying an additional 2,982 shares in the last quarter. Bank of America Corp DE lifted its stake in Stemline Therapeutics by 56.8% in the 4th quarter. Bank of America Corp DE now owns 10,669 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 3,866 shares in the last quarter. Great West Life Assurance Co. Can purchased a new position in Stemline Therapeutics in the 4th quarter valued at about $47,000. Finally, MetLife Investment Advisors LLC lifted its stake in Stemline Therapeutics by 54.6% in the 3rd quarter. MetLife Investment Advisors LLC now owns 18,474 shares of the biopharmaceutical company’s stock valued at $307,000 after buying an additional 6,527 shares in the last quarter. 64.82% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: “Stemline Therapeutics Inc (STML) CEO Ivan Bergstein Sells 55,073 Shares” was first published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://sportsperspectives.com/2019/03/15/stemline-therapeutics-inc-stml-ceo-ivan-bergstein-sells-55073-shares.html.

About Stemline Therapeutics

Stemline Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma.

Recommended Story: What is Compound Interest?

Insider Buying and Selling by Quarter for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.